DK1596868T3 - Fremgangsmåde til behandling af hjertesvigt og medikament dertil - Google Patents

Fremgangsmåde til behandling af hjertesvigt og medikament dertil

Info

Publication number
DK1596868T3
DK1596868T3 DK04713672T DK04713672T DK1596868T3 DK 1596868 T3 DK1596868 T3 DK 1596868T3 DK 04713672 T DK04713672 T DK 04713672T DK 04713672 T DK04713672 T DK 04713672T DK 1596868 T3 DK1596868 T3 DK 1596868T3
Authority
DK
Denmark
Prior art keywords
drug
heart failure
treating heart
treating
failure
Prior art date
Application number
DK04713672T
Other languages
Danish (da)
English (en)
Inventor
Osamu Sato
Atsushi Ozaki
Yosuke Maki
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1596868(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of DK1596868T3 publication Critical patent/DK1596868T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04713672T 2003-02-24 2004-02-23 Fremgangsmåde til behandling af hjertesvigt og medikament dertil DK1596868T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (1)

Publication Number Publication Date
DK1596868T3 true DK1596868T3 (da) 2008-12-08

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04713672T DK1596868T3 (da) 2003-02-24 2004-02-23 Fremgangsmåde til behandling af hjertesvigt og medikament dertil

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP1596868B1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
EP1968990B1 (en) 2005-12-27 2015-02-11 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
UA99914C2 (ru) * 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
BR112012021347A2 (pt) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
EP4353203B1 (en) 2015-03-20 2026-08-19 JenaValve Technology, Inc. Heart valve prosthesis delivery system
EP3632378B1 (en) 2015-05-01 2024-05-29 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
WO2017195125A1 (en) 2016-05-13 2017-11-16 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
EP3573579B1 (en) 2017-01-27 2023-12-20 JenaValve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
EP0602209A1 (en) 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
BR0017074A (pt) 2000-01-26 2002-12-03 Warner Lambert Co Combinações de inibidor de ace-antagonista de vasopressina
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
IL145684A (en) * 2000-10-04 2007-06-17 Warner Lambert Co Medications for the treatment of pulmonary hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
MXPA05001623A (es) 2005-04-25
JP2011148806A (ja) 2011-08-04
JP2006518731A (ja) 2006-08-17
RU2005102110A (ru) 2005-09-20
EP1596868A4 (en) 2006-03-29
PL404315A1 (pl) 2013-08-05
ES2315640T3 (es) 2009-04-01
CY1108583T1 (el) 2014-04-09
CA2493475A1 (en) 2004-09-02
BRPI0405657A (pt) 2005-07-19
MY143740A (en) 2011-07-15
JP4771937B2 (ja) 2011-09-14
CN100577171C (zh) 2010-01-06
EP2000142A1 (en) 2008-12-10
US7749993B2 (en) 2010-07-06
NO20050569L (no) 2005-11-22
TW200418489A (en) 2004-10-01
KR100706727B1 (ko) 2007-04-12
AU2004212842B9 (en) 2009-03-05
DE602004017283D1 (de) 2008-12-04
AR043259A1 (es) 2005-07-20
NO335369B1 (no) 2014-12-01
PL373432A1 (en) 2005-08-22
PT1596868E (pt) 2009-01-14
WO2004073716A1 (en) 2004-09-02
TWI322689B (en) 2010-04-01
RU2008133654A (ru) 2010-02-20
KR20050105972A (ko) 2005-11-08
HK1084037A1 (zh) 2006-07-21
NO20050569D0 (no) 2005-02-02
AU2009201109A1 (en) 2009-04-09
SI1596868T1 (sl) 2008-12-31
CN1700919A (zh) 2005-11-23
US20050187210A1 (en) 2005-08-25
US20080214523A1 (en) 2008-09-04
RU2346689C2 (ru) 2009-02-20
US7423032B2 (en) 2008-09-09
EP1596868B1 (en) 2008-10-22
EP1596868A1 (en) 2005-11-23
ATE411803T1 (de) 2008-11-15
AU2004212842B2 (en) 2009-01-08
PL218069B1 (pl) 2014-10-31
AU2004212842A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
IS7977A (is) Samsetningar og aðferð til samsettra meðferðar
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
DK1539224T3 (da) Antimikrobielt præparat og fremgangsmåde til anvendelse
DK1673214T3 (da) Apparat og fremgangsmåde til behandling af slam
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK2878297T3 (da) Lægemidler til behandling og forebyggelse af fibrotiske sygdomme
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK1667986T3 (da) Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf
DK1679058T3 (da) Farmaceutisk sammensætning til behandling af kardiovaskulære og cerebrovaskulære sygdomme
DK1539115T3 (da) Fremgangsmåder og doseringsformer til kontrolleret levering af paliperidon
NO20031053D0 (no) Middel og framgangsmåte for syrebehandling av underjordiske formasjoner
DE60326368D1 (de) Herstellungsverfahren eines implantierbaren medizinischen leiters
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
IS8082A (is) Inndælingarbúnaður án nálar og aðferð til inndælingar
DK1768489T3 (da) Apparat og fremgangsmåde til destruktion af vegetation
DK1599469T3 (da) Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed
NO20053874D0 (no) Formulering og metoder for behandling av thrombocytemi
DK1520587T3 (da) Allergivaccinesammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf til allergibehandling
IS7572A (is) Aðferð og efni til lækninga
DK1364691T3 (da) Forlystelsesindretning og fremgangsmåde til anvendelse af en forlystelsesindretning
NO20044012D0 (no) Fremgangsmate og et system
IS2654B (is) Essítalópram hýdróbrómíð og aðferð til framleiðslu þess
DK1611890T3 (da) Fremgangsmåde til evaluering og behandling af cancer